Skip to main content

Advertisement

Table 1 Patient characteristics in the entire cohort and according to central HER2 status

From: MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer

  Entire cohort HER2-negative HER2-positive p value
N (%) 229 90 (39.3 %) 139 (60.7 %)  
Age (years)
 Median (range) 57 (28–95) 59 (32–79) 55 (28–95) 0.035
  1. CT chemotherapy, RT radiotherapy
  2. Significant p values are shown in italics
  N % N % N % p value
Menopausal status
 Pre 71 31 28 31.1 43 30.9 0.98
 Post 158 69 62 68.9 96 69.1  
Performance status (N = 225)
 0 164 72.9 63 70.8 101 74.3 0.38
 1 47 20.9 18 20.2 29 21.3  
 2–3 14 6.2 8 9 6 4.4  
History (N patients with available data)
 Adjuvant CT (N = 228) 133 58.3 55 61.8 78 56.1 0.40
 Adjuvant CT anthracycline (N = 227) 90 39.6 29 33 61 43.9 0.10
 Adjuvant CT taxanes (N = 227) 55 24.2 17 19.3 38 27.3 0.17
 Adjuvant RT (N = 224) 87 38.8 35 39.8 52 38.2 0.82
 Adjuvant HT (N = 227) 108 47.6 45 51.1 63 46.3 0.48
Line of treatment
 1st line 192 83.8 68 75.6 124 89.2  
 2nd line 31 13.5 18 20.0 13 9.4  
 3rd line 2 0.9 2 2.2 0 0.0  
 4th line 2 0.9 1 1.1 1 0.7  
 5th line 1 0.4 0 0.0 1 0.7  
 6th line 0 0.0 0 0.0 0 0.0  
 7th line 1 0.4 1 1.1 0 0.0  
Histological grade (N = 214)
 I–II 94 43.9 40 47.6 54 41.5 0.38
 III 120 56.1 44 52.4 76 58.5  
Metastatic sites
 Locoregional 73 31.9 28 31.1 45 32.4 0.84
 Distant 203 88.6 83 92.2 120 86.3 0.17
 Bones 98 42.8 41 45.6 57 41.3 0.53
 Visceral 155 67.7 60 66.7 95 68.3 0.79
Number of metastatic sites
 <3 166 72.4 65 72.2 101 72.7 0.87
 ≥3 63 27.6 25 27.8 38 27.3  
  1. CT chemotherapy, RT radiotherapy
  2. Significant p values are shown in italics